LOVAZA

LOE Approaching

omega-3-acid ethyl esters

NDAORALCAPSULE
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal β-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. LOVAZA may reduce the synthesis of TG…

Clinical Trials (5)

NCT02839902Phase 4Completed

Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood

Started Dec 2016
53 enrolled
Hyperlipidemia
NCT02824432Phase 4Completed

Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation

Started Aug 2016
37 enrolled
Hyperlipidemia
NCT02189252Phase 1Completed

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

Started Oct 2014
30 enrolled
Severe Hypertriglyceridemia
NCT01301794Phase 4Unknown

Lovaza Mechanisms of Action

Started Aug 2012
40 enrolled
Moderate Hypertriglyceridemia.
NCT01594983Phase 2Completed

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Started Jun 2012
58 enrolled
Non Familial Chylocmicronemia Syndrome (Non-FCS)